{{chembox
| verifiedrevid = 443425952
|ImageFile=Bradykinin structure.svg
|ImageFile1=Bradykinin_updated.png
|ImageSize=
|IUPACName=
|OtherNames=
|Section1= {{Chembox Identifiers
|  ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 388341
| InChI = 1/C50H73N15O11/c51-32(16-7-21-56-49(52)53)45(72)65-25-11-20-39(65)47(74)64-24-9-18-37(64)43(70)58-28-40(67)59-34(26-30-12-3-1-4-13-30)41(68)62-36(29-66)46(73)63-23-10-19-38(63)44(71)61-35(27-31-14-5-2-6-15-31)42(69)60-33(48(75)76)17-8-22-57-50(54)55/h1-6,12-15,32-39,66H,7-11,16-29,51H2,(H,58,70)(H,59,67)(H,60,69)(H,61,71)(H,62,68)(H,75,76)(H4,52,53,56)(H4,54,55,57)/t32-,33-,34-,35-,36-,37-,38-,39-/m0/s1
| InChIKey = QXZGBUJJYSLZLT-FDISYFBBBG
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 406291
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C50H73N15O11/c51-32(16-7-21-56-49(52)53)45(72)65-25-11-20-39(65)47(74)64-24-9-18-37(64)43(70)58-28-40(67)59-34(26-30-12-3-1-4-13-30)41(68)62-36(29-66)46(73)63-23-10-19-38(63)44(71)61-35(27-31-14-5-2-6-15-31)42(69)60-33(48(75)76)17-8-22-57-50(54)55/h1-6,12-15,32-39,66H,7-11,16-29,51H2,(H,58,70)(H,59,67)(H,60,69)(H,61,71)(H,62,68)(H,75,76)(H4,52,53,56)(H4,54,55,57)/t32-,33-,34-,35-,36-,37-,38-,39-/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = QXZGBUJJYSLZLT-FDISYFBBSA-N
| CASNo_Ref = {{cascite|correct|CAS}}
| CASNo=58-82-2
|  PubChem = 439201
| IUPHAR_ligand = 649
|  UNII_Ref = {{fdacite|correct|FDA}}
| UNII = S8TIM42R2W
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 3165
| SMILES = O=C(N[C@H](C(=O)N[C@H](C(=O)O)CCC/N=C(\N)N)Cc1ccccc1)[C@H]5N(C(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H]3N(C(=O)[C@H]2N(C(=O)[C@@H](N)CCC/N=C(\N)N)CCC2)CCC3)Cc4ccccc4)CO)CCC5
|  MeSHName=Bradykinin
  }}
|Section2= {{Chembox Properties
|  Formula=C<sub>50</sub>H<sub>73</sub>N<sub>15</sub>O<sub>11</sub>
|  MolarMass=1060.21 g/mol
|  Appearance=
|  Density=
|  MeltingPt=
|  BoilingPt=
|  Solubility=
  }}
}}
{{protein
|Name=[[激肽原1|激肽原1]]
|caption=
|image=
|width=
|HGNCid=6383
|Symbol=[[激肽原1|KNG1]]
|AltSymbols=KNG, BDK
|EntrezGene=3827
|OMIM=612358
|RefSeq=NM_001102416
|UniProt= P01042
|PDB=
|ECnumber=
|Chromosome=3
|Arm=q
|Band=21
|LocusSupplementaryData=-qter
}}
{{Infobox protein family
| Symbol = 缓激肽
| Name = 缓激肽
| image = 
| width = 
| caption = 
| Pfam = PF06753
| Pfam_clan =  
| InterPro = IPR009608
| SMART = 
| PROSITE = 
| MEROPS = 
| SCOP = 
| TCDB = 
| OPM family = 
| OPM protein = 
| CAZy = 
| CDD = 
}}
'''缓激肽'''（{{lang-en|Bradykinin}}）是引起[[血管|血管]]扩张的一种[[肽|肽]]，因此导致[[血压|血压]]降低。一类名叫[[ACE抑制药|ACE抑制药]]的用于降血压的药物会增加缓激肽的浓度（通过抑制其降解）进而降低血压。缓激肽是通过释放[[前列环素|前列环素]]、[[一氧化氮|一氧化氮]]以及[[内皮衍生的超极化因子|内皮衍生的超极化因子]]作用于血管的。

缓激肽是一种具生理学与药理学活性的[[肽|肽]]，是蛋白质的[[激肽|激肽]]类成员之一，由九个[[氨基酸|氨基酸]]组成。

==结构==
[[File:Bradykinin_structure.svg|thumb]]
缓激肽是一种含有九个氨基酸的[[转录_(遗传学)|肽链]]。缓激肽的[[氨基酸|氨基酸]]序列是 [[精氨酸|Arg]]-[[脯氨酸|Pro]]-Pro-[[甘氨酸|Gly]]-[[苯丙氨酸|Phe]]-[[丝氨酸|Ser]]-Pro-Phe-Arg (RPPGFSPFR)。其化學式为C<sub>50</sub>H<sub>73</sub>N<sub>15</sub>O<sub>11</sub>。

==合成==
[[激肽-激肽释放酶系统|激肽-激肽释放酶系统]]通过[[蛋白酶解|溶蛋白性裂解]]其激肽原前体而产生出缓激肽，这里的激肽原前体是[[高分子量激肽原|高分子量激肽原]]（HMWK或HK），完成此过程的酶为[[激肽释放酶|激肽释放酶]]。

==代谢==
在人体中，缓激肽被三种激肽酶降解：[[血管紧张素转化酶|血管紧张素转化酶]]（ACE）、氨肽酶P（APP）以及[[羧肽酶|羧肽酶]]N（CPN），他们分别切割7～8、1～2和8～9号位肽键<ref name="pmid11299220">{{cite journal | author = Dendorfer A, Wolfrum S, Wagemann M, Qadri F, Dominiak P | title = Pathways of bradykinin degradation in blood and plasma of normotensive and hypertensive rats | journal = Am. J. Physiol. Heart Circ. Physiol. | volume = 280 | issue = 5 | pages = H2182–8 | pmid = 11299220 | doi = | url =  |date=May 2001}}</ref><ref name="pmid10749699">{{cite journal | author = Kuoppala A, Lindstedt KA, Saarinen J, Kovanen PT, Kokkonen JO | title = Inactivation of bradykinin by angiotensin-converting enzyme and by carboxypeptidase N in human plasma | journal = Am. J. Physiol. Heart Circ. Physiol. | volume = 278 | issue = 4 | pages = H1069–74 | pmid = 10749699 | doi = | url =  |date=April 2000}}</ref>。

==生理学作用（功能）==
===效应===
缓激肽是一种强大的[[内皮|内皮]]依赖性[[血管舒張|血管舒张剂]]，会导致非血管的[[平滑肌|平滑肌]]收缩，增加[[血管通透性|血管通透性]]并且亦涉及到[[疼痛|疼痛]]的机制。缓激肽也会导致[[尿钠增多|尿钠增多]]，有助于降低血压。

缓激肽会使[[新皮质|新皮质]]的[[星形膠質細胞|星形膠質細胞]]内部[[钙|钙]]离子水平升高，致使它们释放[[谷氨酸|谷氨酸]]<ref name="pmid7911978">{{cite journal | author = Parpura V, Basarsky TA, Liu F, Jeftinija K, Jeftinija S, Haydon PG | title = Glutamate-mediated astrocyte-neuron signalling | journal = Nature | volume = 369 | issue = 6483 | pages = 744–7 | pmid = 7911978 | doi = 10.1038/369744a0 | url =  |date=June 1994}}</ref>。

在某些使用[[血管紧张素Ⅰ转化酶|血管紧张素Ⅰ转化酶]]（ACE）抑制药的病人中，缓激肽被认为是导致干咳的诱因。这种难以治疗的咳嗽通常是由于停止[[ACE抑制药|ACE抑制药]]的治疗而导致的。在此种情况下，[[血管紧张素Ⅱ受体拮抗剂|血管紧张素Ⅱ受体拮抗剂]]被用于下一步治疗。

缓激肽的活性过高被认为在一种名叫[[遗传性血管性水肿|遗传性血管性水肿]]的罕见疾病中扮演了角色，这种病曾被称为遗传性血管-神经水肿<ref name="pmid17620062">{{cite journal | author = Bas M, Adams V, Suvorava T, Niehues T, Hoffmann TK, Kojda G | title = Nonallergic angioedema: role of bradykinin | journal = Allergy | volume = 62 | issue = 8 | pages = 842–56 | pmid = 17620062 | doi = 10.1111/j.1398-9995.2007.01427.x | url =  |date=August 2007}}</ref>。

分娩后婴儿首次分泌的缓激肽会导致[[动脉导管|动脉导管]]收缩并最终使其退化，形成肺动脉干与主动脉弓之间的动脉韧带。

===受体===
{{Main|缓激肽受体}}
* B<sub>1</sub>受体（亦称为[[缓激肽受体B1|缓激肽受体B<sub>1</sub>]]）仅在作为组织受伤的结果下被表达，并推测其在慢性疼痛之中起作用。亦发现这一受体在[[炎症反应|炎症反应]]中起到作用<ref name="pmid10934225">{{cite journal | author = McLean PG, Ahluwalia A, Perretti M | title = Association between Kinin B1 Receptor Expression and Leukocyte Trafficking across Mouse Mesenteric Postcapillary Venules | journal = J. Exp. Med. | volume = 192 | issue = 3 | pages = 367–80 | pmid = 10934225 | pmc = 2193221 | doi = 10.1084/jem.192.3.367| url =  |date=August 2000}}</ref>。最近，现已表明激肽B<sub>1</sub>受体会通过产生趋化因子[[CXCL5|CXCL5]]而招募[[嗜中性粒细胞|嗜中性粒细胞]]。此外，现发现[[内皮|内皮]]细胞是这一B<sub>1</sub>受体-CXCL5通路的潜在来源<ref name="pmid17878384">{{cite journal | author = Duchene J, Lecomte F, Ahmed S, Cayla C, Pesquero J, Bader M, Perretti M, Ahluwalia A | title = A novel inflammatory pathway involved in leukocyte recruitment: role for the kinin B1 receptor and the chemokine CXCL5 | journal = J. Immunol. | volume = 179 | issue = 7 | pages = 4849–56 | pmid = 17878384 | doi = | url =  |date=October 2007}}</ref>。

* The B<sub>2</sub>受体是组成型表达产物且参与缓激肽的血管舒张作用。

激肽B<sub>1</sub>与B<sub>2</sub>受体属于G蛋白偶联受体（[[GPCR|GPCR]]）家族。

==历史==
缓激肽于1948年由三名工作于[[Maurício_Rocha_e_Silva|Maurício Rocha e Silva]]领导的[[巴西|巴西]][[圣保罗_(巴西)|圣保罗]]生物学会中[[巴西|巴西]]生理学家与药理学家发现的。

==用于治疗的可能性==

==另见==
*[[低血压输血反应|低血压输血反应]]

==参考文献==
{{Reflist|2}}

{{神经肽}}
{{Peptidergics}}
{{自身活性物质}}

[[Category:肽类激素|Category:肽类激素]]
[[Category:激肽系统|Category:激肽系统]]